FREDERICK, MD, Nov. 27, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced that the U.S. Food & Drug Administration (FDA) declined the company’s 510(k) submission for ActiPatch®, intended for seeking expanded over-the-counter (OTC) indications for the treatment of musculoskeletal pain. In the back pain … Continue Reading
Author Archives
ianwar@bielcorp.com
BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain
FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effective Electroceuticals,” the article provides insights into how electroceuticals (devices that provide electrical therapy) are set … Continue Reading
BioElectronics’ President Discusses ActiPatch’s® Opioid Application
PHOENIX, Sept. 11, 2018 (GLOBE NEWSWIRE) — President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) goes back onto the “Stock Day” podcast. BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of the unique product line of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; … Continue Reading
BioElectronics Applies for FDA’s Opioid Alternative Innovation Challenge Program
FREDERICK, MD, Aug. 13, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration’s 2018 Opioid Innovation Challenge. This challenge was designed by the FDA to spur the development/deployment of medical devices that can help combat the opioid … Continue Reading
BioElectronics ActiPatch Musculoskeletal Therapy Added to Mundipharma Australia’s Pain Portfolio
FREDERICK, MD, July 23, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited (Mundipharma), https://www.mundipharma.com.au/ has added ActiPatch® to its pain management portfolio, by acquiring the exclusive Australian and New Zealand distribution rights to the ActiPatch® Musculoskeletal Pain Therapy medical device. “The addition of ActiPatch® to our existing pain medications … Continue Reading
BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain
FREDERICK, MD, July 12, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that a Traditional 510(k) Premarket Notification for ActiPatch® was filed today with the U.S. Food and Drug Administration (FDA). The market clearance requested was “over-the-counter adjunctive use in the treatment of musculoskeletal pain”. While ActiPatch is already FDA-cleared for … Continue Reading
BioElectronics Corporation’s President Andy Whelan Joins Everett Jolly on “Stock Day” to Discuss Progress
PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) — Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) back onto the “Stock Day” podcast. Andy spoke with Everett about their progress in the US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities. BioElectronics Corporation is … Continue Reading
Braun Medical Includes BioElectronics ActiPatch Medical Device in Its Same Day Knee and Hip Surgical Program
FREDERICK, MD., May 31, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), maker of advanced medical devices announces that B. Braun Ltd, of Sheffield, UK has recently completed development of its same day surgical TOTAL Pathway program for joint replacements which includes BioElectronics medical devices. The program is being launched by B. Braun’s UK … Continue Reading
BioElectronics Receives FDA Pre-Submission Approval for its Post-Operation Pain Market Clearance Application
FREDERICK, MD, May 29, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com reports that it has cancelled today’s scheduled US Food and Drug Administration meeting. “The FDA’s response to our questions, suggestions, and instructions are more than adequate for us to proceed with filing of the formal 510(k) Market Clearance Application,” stated Ian … Continue Reading
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what … Continue Reading